BioSpace News Archive

Harmony Biosciences Holdings, Inc. reported preliminary, unaudited fourth quarter and full year 2023 net product revenue growth of more than 30 percent.

Rigel Pharmaceuticals, Inc. provided a business update including preliminary total revenue for the fourth quarter of 2023, ongoing activity from the commercial portfolio, including TAVALISSE® tablets and REZLIDHIA® capsules, and upcoming catalysts for 2024.

AtriCure, Inc. announced preliminary financial results for the fourth quarter and full year 2023 and provided 2024 financial guidance.

As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation today announced that it has granted a total of 50,000 restricted stock units (“RSUs”) and 70,000 shares subject to the Company’s executive compensation programs.

Bayer today announced positive top-line results of the pivotal Phase III studies OASIS 1 and 2 evaluating the efficacy and safety of the investigational compound elinzanetant versus placebo.

Tandem Diabetes Care’s t:slim X2 ™ Insulin Pump is the First Automated Insulin Delivery System to Integrate with Abbott’s New FreeStyle Libre ® 2 Plus Sensor.

Butterfly Network, Inc. today announced the FDA clearance of its next-generation handheld point-of-care ultrasound (POCUS) system, Butterfly iQ3.

Yield10 Bioscience, Inc. today announced that the Company recently filed a request for a Regulatory Status Review (“RSR”) with USDA-APHIS Biotechnology Regulatory Services for proprietary elite Camelina sativa (“Camelina”) varieties designed to produce seed oil containing both essential omega-3 fatty acids eicosapentaenoic acid (“EPA”) and docosahexaenoic acid (“DHA”).

Veru Inc. today announced submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration for the development of enobosarm for obesity.

CVRx, Inc., a commercial-stage medical device company, announced certain preliminary unaudited fourth quarter and full year 2023 revenue results as well as its 2024 business outlook.